Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Absolute Bioavailability and Pharmacokinetics of BI 409306 Using a Single Oral Dose of BI 409306 Co-administered With an Intravenous Stable Labeled Isotope BI 409306 (C-13/N-15) in Healthy Male and Female Subjects (Non-Randomised, Open-label, Single Arm, Single Period Design)

Trial Profile

Absolute Bioavailability and Pharmacokinetics of BI 409306 Using a Single Oral Dose of BI 409306 Co-administered With an Intravenous Stable Labeled Isotope BI 409306 (C-13/N-15) in Healthy Male and Female Subjects (Non-Randomised, Open-label, Single Arm, Single Period Design)

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs BI 409306 (Primary) ; BI 409306 (Primary)
  • Indications Alzheimer's disease; Cognition disorders; Psychotic disorders; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 06 Jun 2018 Status changed from recruiting to completed.
    • 10 May 2018 Status changed from not yet recruiting to recruiting.
    • 25 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top